Phase 2 N=12 Secretin Infusion for Pain Due to Chronic Pancreatitis
Chronic Pancreatitis
Primary: VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. — 5.71; 6.04; 4.92; 4.87 units on a scale — p=.25
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=705 Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
Chronic Sinusitis With or Without Nasal Polyps
Primary: Adverse Events — 270 participants
Phase 2 N=640 A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.
Asthma
Primary: Rate of Severe Asthma Exacerbations During 6 Months — 0.31; 0.31; 0.26; 0.20 Exacerbations per 6 month — p=0.119
Phase 3 N=1,058 Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
Complicated Intra-Abdominal Infection
Primary: Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA). — 337; 349; 37; 30…
Phase 3 N=611 Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
Varicella
Primary: Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL — 97.2; 97.2…
Phase 4 N=156 Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients
Type 2 Diabetes Mellitus (T2DM)
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks Between Treatment Groups — -1.01; -0.11 percentage of glycosylated haemoglobin — p=< 0.001
N/A N=110 TX2® Low Profile TAA Endovascular Graft
Aortic Aneurysm · Penetrating Ulcer · Vascular Disease
Primary: Patients With Major Adverse Events (MAE) — 2; 3 participants — p=< 0.001
Phase 4 N=15 Pregabalin and Post-thoracotomy Pain
Chronic Pain
Primary: The Primary Outcome Measure for the Final Study Will be the Incidence of CPTPS at 2 Months.
N/A N=160 Study of Telbivudine in Chronic Hepatitis B
Chronic Hepatitis B
Primary: HBV-DNA < 300 Copies/mL in 48 Weeks — 79 participants
Phase 2 N=25 Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study
Dyslipidemia
Primary: The Apolipoprotein A-I Fractional Catabolic Rate (FCR) — 0.294; 0.294; 0.295 pools/day — p=>0.5
Phase 4 N=300 Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays
Rhinitis, Allergic, Perennial and Seasonal
Primary: Number of Participants With Overall Preference for Nasal Spray Assessed by Preference Questionnaire. — 96; 59; 30; 57 Participants — p=<0.001
Phase 2 N=46 Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
Adult Primary Hepatocellular Carcinoma · Localized Unresectable Adult Primary Liver Cancer · Recurrent Adult Primary Liver Cancer
Primary: Progression-free Survival — 65 percentage of participants
Phase 2 N=47 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
Brain and Central Nervous System Tumors
Primary: Progression-free Survival (PFS) Rate at 6 Months — 19 percentage of participants
Phase 2 N=18 Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Bladder Cancer · Urinary Bladder
Primary: The Pathologic Complete Response Rate (<pT0) of Neoadjuvant GCS Regimen in Patients With Muscle-invasive Bladder Cancer. — 6.67 percentage of participants
Phase 1 N=90 Prolonged Popliteal Fossa Nerve Blockade (Prolonged Pop)
Postoperative Pain
Primary: Numeric Rating Scale (NRS) Pain Score With Movement — 1.9; 1; 1.3 units on a scale